KLRS
Kalaris Therapeutics, Inc.
Recent 8-K filings for KLRS
Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.
-
May 12, 2026 12:08 UTC earnings item 2.02item 9.01
Kalaris Q1 net loss $10.9M; cash $104.9M; Phase 1b/2 TH103 screening patients
source · KLRS on sec.gov